Combination of Netherton Syndrome and Hypopituitarism with Isolated Somatotropin Deficiency: Case Study

This case study highlights a patient with Netherton syndrome who experienced physical development delays and short stature due to comorbid hypopituitarism with isolated somatotropin deficiency. The patient was treated with the IL-4/13 inhibitor dupilumab and growth hormone therapy, resulting in significant improvement without clinically significant adverse events. The study concludes that addressing physical development delays in Netherton syndrome patients requires investigating the causes of short stature. The combination of growth hormone therapy and dupilumab is effective and safe, emphasizing the need for a multidisciplinary approach in managing such cases.